NY-SOLIDUS-LABS
Solidus Labs , the category-definer for crypto-native market integrity solutions, announced today the launch of HALO , the first automated, comprehensive and testable trade surveillance and market integrity hub tailored for digital assets.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220323005138/en/
HALO’s launch will be instrumental in shaping the future of financial risk monitoring. Built from the ground up to bridge the gap between crypto and traditional finance, HALO provides Wall-Street grade crypto-native regulatory risk and compliance solutions. Increasingly, financial institutions are relying on HALO as they expand into new revenue opportunities offered by digital assets. Beyond a growing client-base of crypto and DeFi businesses, HALO is also set to offer government agencies tools to create transparency, enable innovative regulatory frameworks and ensure safe and regulated crypto financial services in their jurisdictions. The platform addresses numerous crypto-specific challenges, like new market structures, volatility, volumes, data types, decentralized services, trading dynamics, crypto-native market abuse typologies - and evolving business and regulatory demands.
“Crypto’s potential to make financial services more accessible, transparent, liquid and efficient, depends on state-of-the-art financial risk monitoring that enables the merits of digital assets, while surgically mitigating its many new risks,” said Asaf Meir, Founder and CEO of Solidus Labs. “HALO does that by unifying formerly disparate risk data points, and continually monitoring that data in real-time, creating a behavioral-based universal client risk profile that allows our clients to focus on real risk, in real-time, throughout the investment journey.”
Combining cutting edge machine learning technology and decades of traditional financial risk know-how and best practices, HALO is uniquely tailored to address the “triple T” (T3) pillars of market integrity in the crypto and DeFi space - trade surveillance, transaction monitoring, and threat intelligence. HALO’s modules include:
Trade Surveillance: HALO’s comprehensive market surveillance tools ensure market integrity by benchmarking abnormal crypto orders and execution patterns against the market norm, to alert businesses and networks on potential breaches of trading rules or unusual market volatility. HALO users can easily customize detection model sensitivity and backtest against real data in order to meet the needs of quickly evolving regulatory and compliance landscapes.
Transaction monitoring: HALO’s continuous real-time monitoring of crypto and fiat transactions offers unprecedented blockchain-native capabilities and enables detecting, investigating and reporting suspicious crypto deposits and withdrawals for anti-money laundering (AML), sanctions, and financial risk compliance.
Threat Intelligence: Relying on a built-in onboarding verification tool, powerful integrations and crypto-native infrastructure, HALO’s Universal Client Risk Profile aggregates risk across the entire investment journey and multiple markets - from onboarding to trading, post-trade and everything in between. Synthesizing numerous signals into a single threat intelligence hub, HALO surgically surfaces overlooked threats in crypto and DeFi services, enabling businesses to act upon them in real time.
HALO currently protects more than 25 million retail and institutional investors globally, and is actively used to monitor over one trillion events per day. The platform deploys over 50 different proprietary market abuse typologies, shielding investors and safeguarding crypto businesses from new threats unique to the crypto and decentralized finance space. “Since our founding, our deepest commitment has been to enable a safer crypto ecosystem. HALO brings us one step closer to that goal while taking user experience to the next level, empowering risk and compliance teams and allowing crypto businesses to grow safer,” Meir said. “It’s a culmination of thousands of hours of work with crypto teams and discussions with regulators, fulfilling our vision of harnessing crypto not only as an opportunity to transform financial services, but also as an opportunity to take financial risk monitoring into the future.”
To learn more about Solidus Labs and HALO visit: www.soliduslabs.com
About Solidus Labs:
Solidus Labs is the category-definer for crypto-native triple T (T3) market integrity solutions - trade surveillance, transaction monitoring, and threat intelligence.
Our mission is to enable safer crypto trading throughout the investment journey across all centralized and DeFi markets. As the founder of industry leading initiatives like the Crypto Market Integrity Coalition and DACOM Summit , and in everything we do, Solidus is deeply committed to ushering in the financial markets of tomorrow.
Crypto exchanges, financial institutions and regulators globally rely on Solidus HALO - our real time, comprehensive, testable, and future-proof platform. Safeguarding their business from known forms of market abuse and a plethora of emerging crypto-specific risks, we enable our clients to grow faster - and safer.
View source version on businesswire.com: https://www.businesswire.com/news/home/20220323005138/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Cross-Border Private Credit Set to Surge, But Operational Complexity Threatens Momentum, CSC Finds4.12.2025 14:30:00 CET | Press release
79% of GPs expect cross-border private credit deals to grow over the next three years, with more than half forecasting rapid acceleration40% of LPs rejected private credit investment opportunities last year due to reporting or operational concerns92% of LPs say specialist outsourcing enhances transparency Cross-border private credit transactions are poised for strong growth, yet operational complexity is emerging as a critical hurdle. According to CSC, the leading provider of business administration and compliance solutions, an overwhelming 92% of limited partners (LPs) express concern over the complexity of these deals. Published in CSC’s latest report, Private Credit 2025: Global Strategies for a $1.5 Trillion Market, the findings highlight a growing disconnect between investors and fund managers as private credit continues its rapid international expansion. 1 While both LPs and general partners (GPs) remain optimistic about the growth of cross-border private credit, they diverge sha
Pace selected by Prudential Financial to help automate its insurance operations with agentic AI4.12.2025 14:15:00 CET | Press release
Pace’s AI-powered agents are helping to streamline policy service and perform other quality assurance tasks within Prudential’s Individual Life Insurance business Pace, the agentic workforce for insurance, was chosen by Prudential’s Individual Life Insurance (ILI) business to help simplify and improve its service delivery. Pace’s AI-powered agents are now streamlining policy servicing and supporting quality assurance efforts within Prudential’s ILI business. The first set of automated systems is now live taking on thousands of hours of work. “Our work with Prudential is an example of how AI can be used as a strategic advantage,” said Pace CEO Jamie Cuffe. “We’re thrilled to support their exceptional team with AI agents in production today that deliver best-in-class accuracy and speed at significant scale.” This multi-year agreement between Pace and Prudential’s ILI business began as a pilot and quickly moved to full production after demonstrating clear improvements in speed and operati
Redefining Acromegaly Care: First Patient Randomized in Debiopharm’s Phase III OXTEND-03™ Trial of 3-Month Debio 4126 Treatment4.12.2025 14:00:00 CET | Press release
OXTEND-03™ (NCT06930625) is a Phase III, multi-center, randomized trial assessing the efficacy and safety of Debio 4126, the first and only octreotide formulation designed for quarterly (3-month) dosing Debiopharm (www.debiopharm.com), a privately-owned, Swiss-based biopharmaceutical company committed to establishing tomorrow’s standards of care in oncology and rare diseases, today announced that the first patient has been randomized in the OXTEND-03™ clinical trial. This pivotal Phase III trial is designed to evaluate the efficacy and safety of Debio 4126, a novel long-acting octreotide formulation and the first potential 3-month somatostatin analogue (SSA), in adults with acromegaly who are currently maintained on somatostatin analogs. OXTEND-03™ is a global trial spanning approximately 75 sites across 21 countries, aiming to enroll around 120 patients. The primary goal of the trial is to confirm Debio 4126’s ability to maintain biochemical control of the disease while significantly
Visa Launches Global Art Collection to Elevate Creators and Celebrate the FIFA World Cup 26™4.12.2025 14:00:00 CET | Press release
Visa spotlights global illustrators and creative small businesses, teaming up with Pharrell Williams’ JOOPITER to accelerate creator growth. Visa today unveiled the first five pieces in its first-ever global art collection celebrating the cultural energy of the FIFA World Cup 26™. Featuring more than twenty artists from six continents, the collection reflects Visa’s belief that creativity drives commerce—and that today’s creators are the entrepreneurs shaping communities and culture around the world. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251204080105/en/ Darien Birks (Global) Visa debuted the first five pieces in the collection at an exclusive Miami showcase, “The Art of the Draw”, hosted by multidisciplinary creator KidSuper. The showcase featured the works of artists Darien Birks, Nathan Walker, Cesar Canseco, Ivan Roque, and Rafael Mayani that celebrate the culture and traditions of each host country and host cit
Parse Biosciences Launches Evercode Whole Blood Fixation4.12.2025 14:00:00 CET | Press release
New fixation method streamlines blood sample handling for translational research Parse Biosciences, a leading provider of accessible and scalable single cell sequencing solutions, today announced the launch of Evercode™ Whole Blood Fixation, a new kit that enables immediate fixation of whole blood directly at the point of collection. The technology eliminates the need for on-site PBMC isolation, specialized equipment, or trained personnel, allowing translational hematology and pharmaceutical research teams to seamlessly collect blood samples in real-world clinical settings for downstream single cell analysis. Traditional single cell RNA profiling workflows done in a translational setting require a compromise between processing fresh samples, which degrade rapidly and demand skilled handling, and using fixation approaches that capture only a partial transcriptome and cannot provide paired TCR sequences. Fresh PBMC isolation also requires complex workflows and specialized reagents. Everc
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom